Tuesday, November 5, 2024
HomeTagsOut-License Agreement

Out-License Agreement

Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, announced a global out-license agreement with AstraZeneca...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics